Non-invasive prediction of hepatic fibrosis in patients with chronic HCV based on the routine pre-treatment workup

Hepatitis Monthly

Volumn 12, Issue 11, 2012, Pages

  Khairy, Marwa ^a   Abdel Rahman, Mahassen ^a   El Raziky, Maissa ^a   El Akel, Wafaa ^a   Zayed, Naglaa ^a   Khatab, Hany ^a   Esmat, Gamal ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Fibrosis; Hepatitis C; Liver cirrhosis

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; GLUCOSE; HEMOGLOBIN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INTERFERON; RIBAVIRIN; SERUM ALBUMIN; THYROTROPIN;

ADULT; APRI SCORE; ARTICLE; BODY MASS; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; LEUKOCYTE COUNT; LIVER BIOPSY; LIVER FIBROSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PLATELET COUNT; PREDICTIVE VALUE; PROTHROMBIN TIME; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

EID: 84875715006     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.6718     Document Type: Article

References (32)

1. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 Suppl 1:74-81.
2. Seeff LB. The history of the “natural history” of hepatitis C (1968-2009). Liver Int. 2009;29 (Suppl 1):89-99.
3. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55(2):245-64.
4. El-Zanaty F, Way A. Egypt Demographic and Health Survey 2008. Journal [serial on the Internet]. 2009 Date: Available from: http://www.measuredhs.com/pubs/pdf/FR220/FR220.pdf.
5. El-Zanaty FH, Way AA, al-Sihhah wa al EW, Macro O. Egypt demographic and health survey, 2005. Ministry of Health and Population; 2006.
6. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-74.
7. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology. 2006;44(6):1675-84.
8. Reiss G, Keeffe EB. Role of liver biopsy in the management of chronic liver disease: selective rather than routine. Rev Gastroenterol Disord. 2005;5(4):195-205.
9. Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology. 2006;43(2 Suppl 1):S113-20.
10. Massard J, Ratziu V, Thabut D, Moussalli J, Lebray P, Benhamou Y, et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol. 2006;44(1 Suppl):S19-24.
11. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24(2):289-93.
12. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Con-jeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518-26.
13. Fix OK, Horsburgh CR, Heeren TC, et al. The performance of APRI for the diagnosis of significant hepatic fibrosis is improved by a simple modification. 2005 Nov 11-15; San Francisco. AASLD; 2005.
14. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-25.
15. Castera L, Bernard PH, Le Bail B, Foucher J, Trimoulet P, Mer-rouche W, et al. Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers. Aliment Pharmacol Ther. 2011;33(4):455-65.
16. Kim CW, Yoon SK, Jo BS, Shin JY, Jang JW, Choi JY, et al. [Prediction of hepatic fibrosis using serum hyaluronic acid in patients with chronic liver disease]. Korean J Gastroenterol. 2003;42(6):510-8.
17. Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol. 2008;32(6 Suppl 1):22-39.
18. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med. 2004;10(4):429-34.
19. de Torres M, Poynard T. Risk factors for liver fibrosis progression in patients with chronic hepatitis C. Ann Hepatol. 2003;2(1):5-11.
20. Pradat P, Voirin N, Tillmann HL, Chevallier M, Trepo C. Progression to cirrhosis in hepatitis C patients: an age-dependent process. Liver Int. 2007;27(3):335-9.
21. Hayashida K, Shoji I, Deng L, Jiang DP, Ide YH, Hotta H. 17beta-estradiol inhibits the production of infectious particles of hepatitis C virus. Microbiol Immunol. 2010;54(11):684-90.
22. Rigamonti C, Andorno S, Maduli E, Capelli F, Boldorini R, Sartori M. Gender and liver fibrosis in chronic hepatitis: the role of iron status. Aliment Pharmacol Ther. 2005;21(12):1445-51.
23. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130(6):1636-42.
24. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53(3):726-36.
25. Al Ashgar H, Helmy A, Khan MQ, Al Kahtani K, Al Quaiz M, Rezeig M, et al. Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4. Ann Saudi Med. 2009;29(1):4-14.
26. Sud A, Hui JM, Farrell GC, Bandara P, Kench JG, Fung C, et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology. 2004;39(5):1239-47.
27. Chu CW, Hwang SJ, Luo JC, Lai CR, Tsay SH, Li CP, et al. Clinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C. J Clin Gastroenterol. 2001;32(3):240-4.
28. Hu KQ, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol. 2004;99(5):860-5.
29. Ahmad W, Ijaz B, Javed FT, Gull S, Kausar H, Sarwar MT, et al. A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI). BMC Gastroenterol. 2011;11:44.
30. Martinez SM, Fernandez-Varo G, Gonzalez P, Sampson E, Bruguera M, Navasa M, et al. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2011;33(1):138-48.
31. Usluer G, Erben N, Aykin N, Dagli O, Aydogdu O, Barut S, et al. Comparison of non-invasive fibrosis markers and classical liver biopsy in chronic hepatitis C. Eur J Clin Microbiol Infect Dis. 2012;31(8):1873-8.
32. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhal-luin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32-6.